10-Q: Synergy CHC Corp. Q1 2026 Financials Show Revenue Decline

Synergy CHC Corp. reported a significant decrease in revenue for the first quarter of 2026, driven by lower product sales, alongside an increased net loss.

Summary

• Synergy CHC Corp. reported total revenue of $5,492,705 for the three months ended March 31, 2026, a decrease from $8,170,534 in the same period of 2025.
• The company experienced a net loss of $2,568,899 for the quarter, compared to a net income of $876,264 in the prior year's quarter.
• Operating expenses increased to $4,537,915 from $4,216,318, primarily due to higher salaries, benefits, stock-based compensation, and professional fees.
• Interest expense significantly increased to $2,012,121 from $1,095,369, largely due to new debt and amortization of debt discount.
• Cash used in operating activities increased to $2,044,678 from $822,781, reflecting the net loss and changes in working capital.
• The company had a working capital deficit of $503,862 as of March 31, 2026.
• Management has taken steps to address going concern doubts, including amending loan covenants, laying off employees, and establishing an at-the-market equity offering program.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as significantly negative due to the substantial revenue decline, increased net loss, rising debt, and concerns about the company's ability to continue as a going concern, despite some subsequent capital raises.

Positives

• Beverage revenue increased due to new retail distribution.
• The company has established an at-the-market (ATM) equity offering program and subsequently raised $2,673,201 in gross proceeds in April 2026.
• Subsequent to the quarter, the company entered into an equity purchase agreement (ELOC) for potential future stock sales.
• The company's disclosure controls and procedures were evaluated, and while found not effective, management is addressing these issues.

Negatives

• Total revenue decreased by 32.8% to $5,492,705 in Q1 2026 compared to $8,170,534 in Q1 2025.
• Net loss widened to $2,568,899 from a net income of $876,264.
• Gross profit decreased by 36% to $3,970,795 from $6,164,021.
• Operating expenses increased by 7.6% to $4,537,915.
• Interest expense more than doubled to $2,012,121.
• Cash used in operating activities increased by 148.5% to $2,044,678.
• The company has an accumulated deficit of $59,009,920 as of March 31, 2026.
• The company has a working capital deficit of $503,862 as of March 31, 2026.
• Disclosure controls and procedures were found to be not effective.

Risks

• The company has an accumulated deficit of $59,009,920 and a working capital deficit of $503,862 as of March 31, 2026, raising substantial doubt about its ability to continue as a going concern.
• A significant decrease in net revenue ($2,677,829) and net income ($3,445,163) in the first quarter of 2026 compared to the prior year.
• Increased cash burn from operating activities ($2,044,678 in Q1 2026 vs. $822,781 in Q1 2025).
• The company's disclosure controls and procedures were not effective, indicating potential issues with timely and accurate reporting.
• The company is subject to significant debt obligations and covenants, with a recent amendment to its credit agreement adjusting payment terms and covenants.
• The company has experienced a significant increase in interest expense due to new debt and amortization of debt discount.
• The company has a concentration of revenue from a few major customers (85% from three customers in Q1 2026) and accounts payable from a few vendors (57% from two vendors in Q1 2026), increasing dependency and risk.
• The company has a license agreement termination in February 2026 that resulted in a reversal of $1,500,000 in license fee revenue recognized in March 2025.

Future Outlook

The company intends to organically grow its current product lines by developing and launching new products and expanding into new markets, specifically focusing on increased distribution for its ready-to-drink beverage. Additionally, Synergy CHC Corp. continues to evaluate strategic acquisition opportunities.

Management Comments

• Management acknowledges responsibility for the preparation and presentation of the unaudited condensed interim financial statements, including responsibility for significant accounting estimates and the choice of accounting principles and methods.
• Management evaluated its ability to meet its obligations and concluded that steps taken, including loan amendments, employee layoffs, and ATM equity offering program, alleviate doubts about the company's ability to continue as a going concern.
• Management believes that EBITDA, viewed in addition to, and not in lieu of, reported results in accordance with U.S. GAAP, provides useful information to investors.

Industry Context

StockSavvy.ai notes that Synergy CHC Corp.'s performance in the consumer health care sector, particularly with its FOCUSfactor and Flat Tummy brands, is facing headwinds. The decline in revenue and increase in net loss, coupled with rising interest expenses, highlight the challenges in this competitive market. The company's strategy to grow through new product launches and acquisitions is common in the industry, but execution and funding remain critical.

Comparison to Industry Standards

• The decline in revenue for Synergy CHC Corp. is contrary to the general growth observed in the broader consumer health and wellness market, which has seen steady demand for supplements and lifestyle products.
• The company's increased operating expenses, particularly in general and administrative areas, are higher than typical for companies of similar size in the consumer staples sector, where cost control is paramount.
• The significant increase in interest expense and the resulting negative EBITDA are concerning when compared to industry peers who often maintain positive EBITDA and manage debt more conservatively.
• The company's reliance on a few major customers for a substantial portion of its revenue (85% in Q1 2026) is a higher concentration risk than typically seen in more diversified consumer product companies.

Corporate Governance

Legal Proceedings

• Management believes there are no current legal matters that would have a material effect on the company's financial position or results of operations.

Related Party Transactions

• Consulting fees paid to a company owned by CEO Jack Ross, including advances and expensed amounts.
• A bonus paid to the related party (CEO Jack Ross).
• Prepaid consulting fees balance as of March 31, 2026.
• Vehicle allowance paid to CEO Jack Ross, with a portion expensed and a portion remaining in prepaid expenses.
• Repayment of a short-term note to a related party.
• Advance received in the form of a short-term note from a related party.
• Rent paid to a company owned by CEO Jack Ross, with expensed amounts and a prepaid balance.
• Distribution agreement with Knight Therapeutics (a shareholder) for distribution rights of FOCUSfactor in Canada, including distribution fees and minimum payments.
• Outstanding balance owed to Knight Therapeutics for distribution rights.
• Royalty payments to Knight Therapeutics.

Stakeholder Impact

• Shareholders: Potential dilution from ATM equity offering and ELOC; negative financial performance impacting stock value; concerns about going concern status.
• Employees: 13 employees were laid off to right-size overhead expenses.
• Creditors: Increased interest expense and debt levels; potential impact from covenant adjustments and alleged default on credit agreement.
• Suppliers: Two vendors accounted for 57% of accounts payable as of March 31, 2026, indicating potential leverage for these suppliers.

Next Steps

• Organically grow current product lines by developing and launching new products.
• Expand into new markets.
• Increase distribution for the recently launched ready-to-drink beverage.
• Continue to evaluate strategic acquisition opportunities.
• Seek stockholder approval for issuances in excess of the Beneficial Ownership Limitation at the next annual meeting of stockholders, to be held no later than June 30, 2026.

Key Dates

Recommendation

The company's Q1 2026 results show a significant deterioration in financial performance, with declining revenues, widening losses, and increased debt. The ongoing concerns about the company's ability to continue as a going concern, despite management's efforts and subsequent capital raises, present substantial risk. The ineffective disclosure controls also raise red flags. Therefore, a sell recommendation is warranted given the current financial distress and operational challenges.

Keywords

Synergy CHC Corp, Form 10-Q, Quarterly Report, Financial Statements, Revenue, Net Loss, Operating Expenses, Debt, Going Concern, Consumer Health Care, Nutraceuticals, FOCUSfactor, Flat Tummy